Tags

Type your tag names separated by a space and hit enter

Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma.
Respir Med 2014; 108(9):1355-62RM

Abstract

BACKGROUND

Long-term corticosteroid use may increase cataract risk. The Lens Opacities Classification System (LOCS) III ranked lens opacities as Class 1: 0.5-0.9 unit; Class 2: 1.0-1.4 units; or Class 3: ≥1.5 units in clinical trials of combined mometasone furoate and formoterol (MF/F) administered by metered-dose inhaler (MDI). We examined retrospectively shifts in lenticular opacity in patients with chronic obstructive pulmonary disease (COPD) or asthma.

METHODS

We analyzed pooled LOCS III data from two COPD studies and separately analyzed LOCS III data from an asthma study. COPD subjects were randomized to twice daily MF/F 200/10 μg, MF/F 400/10 μg, MF 400 μg, F 10 μg, and placebo; asthma subjects were randomized to MF/F 200/10 μg, MF/F 400/10 μg, fluticasone propionate/salmeterol (FP/S) 250/50 μg, and FP/S 500/50 μg. Lenticular opacity changes were analyzed post hoc for proportions of subjects with LOCS III grade increases ≥0.5, ≥1.0, or ≥1.5 units at weeks 26 and 52.

RESULTS

Proportions of subjects in the COPD studies with Class 1 (≥0.5 unit), 2 (≥1.0 unit), or 3 (≥1.5 units) increases in LOCS III at week 26 (N = 1675) ranged from 15.5 to 18.6%, 3.3-6.0%, and 0.9-2.2%, respectively. At week 52 (N = 1085), proportions of active-treated subjects with Class 1, 2, or 3 increases in LOCS III ranged from 26.6 to 28.9%, 6.3-10.7%, and 2.6-5.9%, respectively. Treatment differences in lenticular shifts were generally small and nonsignificant in the asthma study.

CONCLUSION

No clinically relevant trends were observed in the LOCS III assessment of lenticular shifts during treatment of COPD and asthma patients, although further study may be needed to confirm the findings presented here. In these trials, MF/F effects on lens opacity were not observed. (Clinicaltrials.gov numbers: NCT00383435, NCT00383721, and NCT00379288.).

Authors+Show Affiliations

Fundacion CIDEA Allergy and Respiratory Research Unit, Buenos Aires, Argentina. Electronic address: maspero@ciudad.com.ar.Respiralab Allergy and Respiratory Center, Kennedy Hospital, Guayaquil, Ecuador.University of Kentucky, Lexington, KY, USA.David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.Medical University of Lodz, Poland.Merck & Co., Inc., Whitehouse Station, NJ, USA.Merck & Co., Inc., Whitehouse Station, NJ, USA.Merck & Co., Inc., Whitehouse Station, NJ, USA.Harvard Medical School, Boston, MA, USA.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25044280

Citation

Maspero, Jorge, et al. "Appraisal of Lens Opacity With Mometasone Furoate/formoterol Fumarate Combination in Patients With COPD or Asthma." Respiratory Medicine, vol. 108, no. 9, 2014, pp. 1355-62.
Maspero J, Cherrez I, Doherty DE, et al. Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. Respir Med. 2014;108(9):1355-62.
Maspero, J., Cherrez, I., Doherty, D. E., Tashkin, D. P., Kuna, P., Kuo, W. L., ... Chylack, L. T. (2014). Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. Respiratory Medicine, 108(9), pp. 1355-62. doi:10.1016/j.rmed.2014.04.015.
Maspero J, et al. Appraisal of Lens Opacity With Mometasone Furoate/formoterol Fumarate Combination in Patients With COPD or Asthma. Respir Med. 2014;108(9):1355-62. PubMed PMID: 25044280.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Appraisal of lens opacity with mometasone furoate/formoterol fumarate combination in patients with COPD or asthma. AU - Maspero,Jorge, AU - Cherrez,Ivan, AU - Doherty,Dennis E, AU - Tashkin,Donald P, AU - Kuna,Piotr, AU - Kuo,Wen-Ling, AU - Gates,Davis, AU - Nolte,Hendrik, AU - Chylack,Leo T,Jr Y1 - 2014/05/02/ PY - 2014/01/02/received PY - 2014/04/18/revised PY - 2014/04/20/accepted PY - 2014/7/22/entrez PY - 2014/7/22/pubmed PY - 2015/6/2/medline KW - Asthma KW - COPD KW - Cataract KW - Inhaled corticosteroid KW - Lenticular opacity SP - 1355 EP - 62 JF - Respiratory medicine JO - Respir Med VL - 108 IS - 9 N2 - BACKGROUND: Long-term corticosteroid use may increase cataract risk. The Lens Opacities Classification System (LOCS) III ranked lens opacities as Class 1: 0.5-0.9 unit; Class 2: 1.0-1.4 units; or Class 3: ≥1.5 units in clinical trials of combined mometasone furoate and formoterol (MF/F) administered by metered-dose inhaler (MDI). We examined retrospectively shifts in lenticular opacity in patients with chronic obstructive pulmonary disease (COPD) or asthma. METHODS: We analyzed pooled LOCS III data from two COPD studies and separately analyzed LOCS III data from an asthma study. COPD subjects were randomized to twice daily MF/F 200/10 μg, MF/F 400/10 μg, MF 400 μg, F 10 μg, and placebo; asthma subjects were randomized to MF/F 200/10 μg, MF/F 400/10 μg, fluticasone propionate/salmeterol (FP/S) 250/50 μg, and FP/S 500/50 μg. Lenticular opacity changes were analyzed post hoc for proportions of subjects with LOCS III grade increases ≥0.5, ≥1.0, or ≥1.5 units at weeks 26 and 52. RESULTS: Proportions of subjects in the COPD studies with Class 1 (≥0.5 unit), 2 (≥1.0 unit), or 3 (≥1.5 units) increases in LOCS III at week 26 (N = 1675) ranged from 15.5 to 18.6%, 3.3-6.0%, and 0.9-2.2%, respectively. At week 52 (N = 1085), proportions of active-treated subjects with Class 1, 2, or 3 increases in LOCS III ranged from 26.6 to 28.9%, 6.3-10.7%, and 2.6-5.9%, respectively. Treatment differences in lenticular shifts were generally small and nonsignificant in the asthma study. CONCLUSION: No clinically relevant trends were observed in the LOCS III assessment of lenticular shifts during treatment of COPD and asthma patients, although further study may be needed to confirm the findings presented here. In these trials, MF/F effects on lens opacity were not observed. (Clinicaltrials.gov numbers: NCT00383435, NCT00383721, and NCT00379288.). SN - 1532-3064 UR - https://www.unboundmedicine.com/medline/citation/25044280/Appraisal_of_lens_opacity_with_mometasone_furoate/formoterol_fumarate_combination_in_patients_with_COPD_or_asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(14)00162-0 DB - PRIME DP - Unbound Medicine ER -